Introduction
When P-glycoprotein (Pgp) was first identified over two decades ago by virtue of its overexpression in multidrugresistant (MDR) tumor cells (Juliano and Ling, 1976) , it sparked the hope that this insidious form of resistance in human tumors could be eradicated. Indeed, this discovery triggered an ongoing search for agents that would inhibit Pgp function, with the hope that by doing so the MDR phenotype could be reversed (Leonard et al., 2002) . However, time has clearly demonstrated that MDR is much more complex than initially believed. First, the role of Pgp in drug response has recently extended far beyond its function as a drug transporter in tumor cells, with numerous studies implicating this protein in the drug biodistribution executed by normal cells (Suzuki and Sugiyama, 2001; Kim, 2002) , and accumulating evidence supporting a role for Pgp in resistance to a much broader range of apoptotic stimuli (Johnstone et al., 2002) . Second, and of considerable consequence to the dissection and conquest of the MDR phenotype, is the identification of several additional members of the ATP-binding cassette (ABC) family of transporters, the MDR-associated proteins (MRPs), which have been functionally implicated in the MDR phenotype (Dean, 2001; Gottesman and Ambudkar, 2001; Borst and Elferink, 2002 for review) . Third, and the stimulus for this review, is emerging evidence that expression of the ABC transporters is highly regulated, particularly at the level of transcription, suggesting a future target for modulation of the MDR phenotype.
Considerable progress has been made towards defining regulatory mechanisms controlling the expression of the MDR1 gene in normal and tumor cells, and these studies have been the subject of several recent reviews Labialle et al., 2002) . Not surprisingly, given the more than 10 years that separated the discovery of Pgp from the identification of the other drug resistance-related ABC transporters, the transcriptional control of the non-Pgp transporters is only now being addressed. Nevertheless, early studies suggest that strong similarities, as well as striking differences, in the regulation of individual drug resistance proteins will be revealed in future investigations. Following a short introduction to the ABC transporter family, this review will address the current literature on transcriptional regulation of the drug resistance-associated ABC transporters, with an emphasis on the control mechanisms governing the expression of the human homologues of each transporter. Although it is recognized that there are multiple mechanisms by which mRNA synthesis can be regulated (splicing, transport, mRNA stability), and indeed some of these mechanisms have already been described for regulation of the drug transporters (Lamba et al., 2003; Yague et al., 2003) , the focus of this review will be limited to those situations in which the regulation of expression has been shown to be mediated at the level of transcription.
ABC transporters and drug resistance
The ABC family of genes are so designated based on the sequence and organization of their ATP-binding domains, and represent the largest family of transmem-brane proteins identified to date. Together, they are responsible for the transport of hundreds of substrates, including hormones, lipids, drugs and other toxins, across both intracellular and extracellular membranes.
The structures of typical ABC transporter are shown in Figure 1 , and discussed in detail elsewhere in this volume and in several recent reviews (Dean and Allikmets, 2001; Gottesman et al., 2002; Kruh et al., 2001; Schinkel and Jonker, 2003) . The family is subdivided based on similarities in domain structure, nucleotide-binding folds and transmembrane domains (Dean, 2001) . Of the 48 family members identified to date, at least 10 have been shown to be involved in resistance to cancer chemotherapeutics, and overexpression of two others has been linked to a drug-resistant phenotype ( Table 1) .
The first ABC transporter whose overexpression was shown to confer the MDR phenotype to drug-naı¨ve cells was Pgp, the product of the MDR1 (ABCB1) gene. Pgp is comprised of 12 transmembrane domains that interact with a wide array of neutral or positively charged hydrophobic substrates and mediate their efflux through hydrolysis of ATP ( Figure 1a ). MRP4 (ABCC4), MRP5 (ABCC5) and the bile salt export protein BSEP (ABCB11, SPGP) share a similar structure with Pgp, while MRP1 (ABCC1), MRP2 (ABCC2, cMOAT), MRP3 (ABCC3) and MRP6 (ABCC6) have five additional transmembrane segments at the N-terminus ( Figure 1b) . BCRP (ABCG2, MXR, ABC-P) is unusual in that it is a 'half-transporter' consisting of six transmembrane domains and one ATP binding site ( Figure 1c) .
Several of the MRPs have been implicated in the transport of negatively charged anionic drugs and neutral drugs conjugated to glutathione, glucuronate or sulfate (Table 1) . MRP4 functions as a cellular efflux pump for purine and nucleoside analogues, including certain antiviral drugs and anticancer agents such as thiopurines and methotrexate . MRP5 also confers resistance to purine and nucleoside analogues, while MRP6 is a glutathione conjugate exporter that is able to confer low levels of resistance to certain anticancer agents, including etoposide, teniposide, doxorubicin and daunorubicin (Belinsky et al., 2002) . MRP8, the newest member of the ABC transporter family implicated in drug efflux, confers resistance to nucleotide analogues such as 5-FU, ddC and PMEA (Guo et al., 2003) . BCRP, the half-transporter, is believed to function as a homodimer for the cellular extrusion of several anticancer agents, including nucleoside analogues, anthracyclines, mitoxantrone and topo- Figure 1 Predicted structure of representative drug transporters from each of the three classes: MDR1 contains 12 transmembrane domains and two nucleotide-binding domains (NBD). The amino-(NH 2 ) and carboxyl (COOH)-termini are designated. MRP1 is similar to MDR1, but includes an additional five transmembrane domains at the N-terminus. BCRP is a 'half-transporter' with one NBD located at the N-terminus tecan. BSEP and ABCA2 have not been as well characterized with respect to a role in drug resistance, but initial studies suggest that they are associated with resistance to paclitaxel (Gottesman et al., 2002) and estramustine (Vulevic et al., 2001) , respectively. An extensive discussion of the structure and function of the ABC drug transporters can be found elsewhere in this volume.
While the focus of this review is on the regulation of ABC transporters that confer drug resistance to human tumors, it is important to note that all these transporters are expressed in normal cells, some ubiquitously and others in a tissue-restricted manner, where they play a role in normal metabolic processes as well as protection against environmental toxins (Table 2 ) (see Borst and Elferink, 2002 for review) . Indeed, mutations in many of these transporters are associated with metabolic disease; for example, hereditary deficiency in MRP2 results in Dubin-Johnson syndrome, while lack of MRP6 causes pseudoxanthoma elasticum, a multisystem disorder affecting the skin, eyes and blood vessels. Thus, given the varied physiological functions of these different transporters, their regulation can be anticipated to require the complex interplay of factors involved in differentiation and development, as well as factors that mediate growth and death decisions elicited by intrinsic and environmental threats.
Transcriptional regulation -an overview
Herculean efforts over the past decade in the area of transcriptional regulation have shown that the fate of a gene is determined by the complexity and accessibility of a myriad of response elements within the promoter, as well as by the complement of transcription factors available to interact with these elements (see Scotto and Ince, 2000 for review) . The composition of these factors is influenced by both the intra-and extracellular milieu, which can vary tremendously during the life of the cell. Thus, dynamic multiprotein complexes form, the nature of which is grossly dictated by promoter architecture yet subtly influenced by different signals, leading to profound regulatory switches. Superimposed upon this regulation is a dynamic chromatin ultrastructure, controlled by cofactors that transduce signals from promoter-bound proteins to the basal transcriptional machinery (Neeley and Workman, 2002) . Thus, it appears that each subset of genes is regulated by specialized multiprotein complexes that include both common basic components (the basal or general transcription factors), as well as unique components that tailor a complex for the transduction of signals initiated by particular developmental, metabolic or environmental stimuli.
Constitutive (uninduced) transcription of the ABC transporters
Almost half of all genes transcribed by RNA polymerase II (Pol II) contain a TATA box. In promoters that contain this element, a first event is the recognition and binding of the TATA box by a general transcription factor, TBP. Through a series of protein-protein interactions, Pol II is recruited to the TATA element and initiates transcription 25-30 nucleotides downstream. How transcription is nucleated in promoters that lack the TATA box (TATAless promoters) is less clear, although many contain an initiator (Inr) element that encompasses the transcription initiation site and conforms to the consensus sequence PY-PY-A( þ 1)-N-T/A-Py-Py (Smale, 1997) . Although both the TATA box and the initiator element seem to serve similar functions with respect to recruitment of the transcription complex, some selectivity in protein requirements suggests a fundamental difference in the way these two classes of promoters are regulated.
Interestingly, all of the human drug-related transporters examined to date lack an appropriately positioned TATA box (the human MRP2 promoter was reported to contain a TATA-like element (Stockel et al., 2000) , but its location over 400 bp upstream of the transcription start site makes it functionally irrelevant), while several of their rodent homologues are TATA-dependent. Transcription of MDR1 is regulated instead by an Inr element, first identified through in vitro studies indicating that deletion of sequences downstream of þ 5 decreased elongation of correctly initiated transcripts to undetectable levels (Cornwell, 1990 ). Transient transfec- tion studies then defined the sequences between À6 and þ 11 as sufficient for proper initiation of transcription in vivo Van Groenigen et al., 1993) . Although Inr's have not yet been functionally described in promoters of other drug transporters, examination of the published sequences identify consensus or nearconsensus Inr's within the promoters of the MRP2 (GTACTTT) and BCRP (CCACTGC) genes (Scotto, unpublished observation) .
GC boxes and CCAAT elements
'GC' elements and 'CCAAT' boxes are among the most ubiquitous Pol II promoter elements and are found in the majority of TATAless promoters. Each element can interact with different families of proteins through sequence-specific DNA recognition. Since mutation or removal of these elements often leads to a complete loss of transcription, the proteins that interact with these elements were initially referred to as constitutive or 'basal' transcription factors. However, this label can be misleading, since more recent studies have shown that these factors are often essential for mediating activation by exogenous agents, particularly those that regulate chromatin structure. For the purpose of this review, these elements will be discussed with respect to both constitutive and inducible expression. Like most 'TATAless' genes, the MDR1 promoter includes both an inverted CCAAT box (À79 to À75) , that interacts with the trimeric transcription factor NF-Y (Hu et al., 2000) and a GCrich element (À56 to À43) that interacts with members of the Sp family of transcription factors, specifically Sp1 and Sp3 (vide infra) (Cornwell and Smith, 1993a, b; Thayer et al., 1996; Sundseth et al., 1997 ) (see Figure 6 for MDR1 promoter structure). Transfection analyses of promoter constructs mutated in one or both of these elements indicate the requirement for each element in the constitutive (i.e. operative under normal growth conditions) expression of MDR1 in some cell lines. Interestingly, early studies suggested that the YB-1 protein, a gene regulatory protein that preferentially interacts with RNA and single-stranded DNA, specifically interacts with the MDR1 inverted CCAAT box to mediate transcription (Ohga et al., 1998) . However, we have shown that YB-1 does not interact with doublestranded oligonucleotides containing the MDR1 CCAAT box; indeed, it interacts only with a singlestranded oligonucleotide containing this element. Moreover, mutations within the MDR1 CCAAT box that abolish transcription and NF-Y binding have no effect on the interaction of YB-1 with the single-stranded oligonucleotide (Hu et al., 2000) , strongly suggesting that NF-Y, not YB-1, is the factor regulating MDR1 through the CCAAT element. Nevertheless, although a direct involvement of YB-1 in MDR1 transcription appears unlikely, a number of studies have linked the expression or nuclear localization of YB-1 with an increase in MDR1 (Bargou et al., 1997; Ohga et al., 1998; Oda et al., 2003; Saji et al., 2003) as well as MRP1 expression (Stein et al., 2001 ). Whether YB-1 is activated in parallel with drug transporters as part of a global stress response or whether there is a direct nontranscriptional role of YB-1 in their regulation remains to be determined.
Upstream within the MDR1 promoter (À110 to À103) lies another GC element that is incapable of interacting with Sp1 (Cornwell and Smith, 1993) , but may interact with another member of the Sp family or the highly related Kruppel factor family of transcription factors (Bieker, 2001) . Immediately downstream and overlapping this GC-rich region is an inverted MED-1 element (À105 to À100) (multiple start site element downstream 1; iMED) that was first described in the hamster MDR1 orthologue, pgp1, and shown to be involved in the activation of that gene in drug-resistant cells Scotto, 1995a, b, 1996) . We (Thayer, 1999) and others (Marthinet et al., 2000; Labialle et al., 2002) have shown that functional disruption of iMED, either through mutation of the element or the use of a transcriptional decoy to sequester iMED-binding proteins, results in a decrease in MDR1 transcription, although a role for this element in resistance-specific activation of the human homologue has yet to be established (vide infra).
GC elements are also important for constitutive expression of a number of other drug transporters. GC elements within the MRP1 promoter (À91 to þ 103) are essential for optimal activity, and Sp1 has been shown to interact with these elements (Zhu and Center, 1996) . The MRP3 proximal promoter contains several GC elements (À86 to À21) that have been shown to interact with Sp1; removal of this region decreases MRP3 transcription (Takada et al., 2000) . The BCRP promoter is TATAless and contains several putative Sp1 binding sites; sequences 300 bp upstream of the transcription start site are sufficient to confer basal promoter activity (Bailey-Dell et al., 2001) . Two functional GC boxes have been identified in the ABCA2 gene; these elements interact with Sp1, Sp3 and the brain-specific Sp4 family member (Davis et al., 2003) . Interestingly, the proximal promoter of MRP2, although TATAless, appears to lack a proximal promoter GC element; a consensus Sp1 site has been identified at position -1709, but has not yet been functionally tested. MRP2 does contain a putative CCAAT box that apparently interacts with YB-1 rather than NF-Y in vitro but this element is not required for constitutive transcription .
Tumor suppressors, oncogenes and MDR1 transcription
High levels of expression of multidrug transporters are often observed in drug-naı¨ve tumors, even when the tissue of origin exhibits little or no expression of the corresponding gene. Hence, constitutive MDR1 or MRP gene expression is likely regulated in some cells by components that are involved in malignant transformation. It has been well established that tumors develop as a result of both uncontrolled proliferation and an intrinsic ability to escape cell death, mediated by the altered expression of various oncogenes and tumor suppressor proteins. Recently, it has become apparent that altered expression of several growth and deathcontrolling proteins can adversely affect drug therapy in two ways: (1) by altering the cell's ability to respond to death signals and (2) by influencing the transcription and thus the expression of drug-resistant genes.
p53
The first evidence that a tumor suppressor protein could influence the expression of a drug-resistant gene came from the observation that wild-type p53 repressed transcription of the MDR1 gene (Chin et al., 1992; Zastawny et al., 1993; Thottassery et al., 1997) . Although a number of mechanisms had been proposed for this repression, our laboratory has recently shown that repression is mediated by a direct interaction of p53 with a novel binding element within the proximal MDR1 promoter (À72 to À40) ( Figure 2 ) , making MDR1 the prototype for a new class of p53-repressed promoters. Binding of p53 to this element, termed the HT (head-to-tail) site, appears to induce a novel tetrameric conformation of p53 that converts p53 from an activator to a repressor, perhaps through the differential recruitment of cofactors. Repression by wild-type p53 has also been reported for the mouse and hamster MDR1 homologues (Zastawny et al., 1993; Bush and Li, 2002) , while other studies suggest an activating role of p53 on the murine mdr1 promoter in response to DNA damage and stress (Mathieu et al., 2001) . Wild-type p53 has also been shown to repress transcription of the human MRP1 promoter (Wang and Beck, 1998; Sullivan et al., 2000; Bahr et al., 2001 ) and loss of p53 expression is correlated with increased MRP1 expression in colorectal cancer (Fukushima et al., 1999) . Although the mechanism mediating the repression of MRP1 has not yet been defined, there is some indication that it may involve deactivation of promoter-bound Sp1 (Wang and Beck, 1998) .
Paradoxically, several common mutant p53 proteins are able to activate, rather than repress, the MDR1 promoter (Chin et al., 1992; Dittmer et al., 1993) ; at least one of these mutants activates MDR1 through a cooperative, and apparently mutant-specific, interaction with the Ets-1 transcription factor at a binding site within the proximal promoter region (À69 to À63) (Sampath et al., 2001 ). This type of direct effect has not been observed with the MRP1 promoter, although it is reasonable to consider that mutations of p53 that inhibit its ability to repress MRP1 transcription could be viewed as indirect 'activators'.
The role of p53 in the regulation of drug resistance genes is not without controversy. Indeed, there are a few cases where opposing effects were observed in different cells or under different conditions (Bahr et al., 2001) . Therefore, the complexity of these systems should not be underestimated, and it is important to keep in mind that the intricate architecture of the individual promoters, the complement of endogenous p53 (mutant or wild type), the presence or absence of other p53 family members, as well as variations in cell-and tissue-specific coeffectors of p53 activity are all likely to influence the ultimate transcriptional readout in a given cell, tissue or tumor type.
Fos/jun (AP-1)
There is some evidence, albeit indirect, that the AP-1 complex may be involved in the transcription of several drug transporters. AP-1 is the general term for transcription factor complexes composed of members of the Fos and Jun oncogene families (Shaulian and Karin, 2001) . AP-1 is constitutively expressed in many cell types, and DNA binding by the complex is induced by serum stimulation, phorbol esters and a variety of growth factors; it is also induced by various stress stimuli.
Elevated levels of c-Fos have been demonstrated in a number of drug-resistant cell lines when compared to their drug-sensitive counterparts (Bhushan et al., 1992; Kim and Beck, 1994; Daschner et al., 1999) . Inhibition of PKA, an inducer of the AP-1 complex, was found to decrease the expression of human MDR1 in the P388 leukemia cell line (Kim and Beck, 1994) ; however, PKA has also been implicated in regulation by SP1 (Rohlff and Glazer, 1998) , complicating the interpretation of these data. A similar line of circumstantial evidence comes from studies of the c-Jun NH2-terminal protein kinase (JNK), which also activates AP-1. In human KB-3 cells, adriamycin, vinblastine and etoposide (VP-16) activate jun kinase (JNK), and this was found to be associated with an increase in MDR1 expression at the mRNA level (Osborne and Chambers, 1996) . Two multidrug-resistant variants of KB-3, KB-A1 and KB-V1, showed increased basal levels of JNK activity when compared to the KB-3 parental cell line.
Putative nonconsensus AP-1 binding sites have been reported in human and rodent class I Pgp promoters. While the AP-1 site in the murine homologue mediates the repression of this gene (Ikeguchi et al., 1991) , the AP-1-binding elements in the promoters of the hamster (À55 to À49) (Teeter et al., 1991a, b) and human genes (À121 to À115) (Daschner et al., 1999) are involved in transcriptional activation. Moreover, cells transfected Figure 2 Schematic of the consensus head-to-head (HH) p53-binding site shown to mediate the activation of target genes by p53 (top) and the nonconsensus head-to-tail (HT) site found within the MDR1 promoter and shown to bind p53 and mediate the repression of MDR1 transcription with c-jun exhibit a higher level of expression of MDR1 RNA and Pgp protein. The MRP1 promoter also contains a putative AP-1 site (À498 to À492) that interacts with a complex containing c-jun and junD (Kurz et al., 2001) . Interestingly, levels of this complex were increased in highly resistant H69AR cells as compared to their parental counterparts, although the role of this element in the regulation of MRP1 in response to inducers has yet to be evaluated fully. Similarly, the MRP2 promoter contains a consensus AP-1-binding element that
has not yet been functionally tested (Tanaka et al., 1999) .
Ras/WT-1
The MDR1 gene is also a target of the ras/raf signaling pathway (Miltenberger et al., 1995; Kim et al., 1997) . Initial studies indicated that signaling by ras converges on the GC-rich binding site for the zinc finger transcription factors Sp1 and Sp3, located within the proximal MDR1 promoter (Miltenberger et al., 1995) . Egr-1, a ubiquitous immediate early factor (reviewed in Thiel and Cibelli, 2002) , and WT-1, the Wilms' tumor suppressor protein (reviewed in Hirose, 1999) , also interact with GC sequences through their zinc-finger domains. Interestingly, both egr1 and WT-1 recognize a site within the MDR1 GC element that overlaps the Sp1/Sp3-binding sequence. Indeed, activation of MDR1 by TPA is mediated by egr-1 (McCoy et al., 1995) and suppressed by WT-1 (McCoy et al., 1999) . A similar GC element resides within the promoters of several MRP genes (supravide), suggesting a potential role for the ras pathway and WT-1 in their regulation as well. It appears, therefore, that the regulation of the expression of MDR1, and perhaps other drug transporters, by ras/ raf and WT1 involves a complex interplay of transcription factors within a very discrete promoter region. To add to this complexity, it has recently been shown that the activation of phospholipase C (PLC) by a variety of inducers activates MDR1 transcription through an upstream element (À106 to -99). This activation is enhanced by coexpression of constitutively active v-raf and blocked by a dominant-negative form of raf or by inhibitors of the mitogen-activated protein kinase (Yang et al., 2001) , suggesting that PLC delivers the ras/raf signal to the MDR1 promoter through a distinct binding site. (Yamada et al., 2003) .
APC

Constitutive overexpression in drug-resistant cells
Tumor cell lines selected for resistance to MDR drugs most often exhibit constitutive overexpression of MDR1 or one of the other MDR-associated transporters.
Although frequently the result of gene amplification, this overexpression can also be mediated at the level of transcription, particularly in the case of the MDR1 gene. Three mechanisms have thus far been described to account for the constitutive overexpression of Pgp and its homologues in drug-selected cell lines. However, it should be noted that any drug-selected mutations/ alterations in any of the factors/pathways that are involved in regulation of the transporters could result in constitutive upregulation, and future studies are likely to identify other mechanisms in other cell types.
MED-1/iMED
The first mechanism described for the constitutive increase in the transcription of a Pgp gene was defined for the hamster pgp1 homologue. During our analysis of the regulation of pgp1, we found that drug-sensitive cells utilize a single transcription start site, while drugresistant cells initiate transcription from several downstream sites (Ince and Scotto, 1995a . Activation of the additional start sites is mediated by a novel downstream element, GCTCCC/G, that we have designated MED-1 (multiple start site element downstream) (Ince and Scotto, 1995b) . The MED-1 element interacts with a multiprotein complex that is currently under investigation (Wright and Scotto, unpublished) and functions within a chromatin complex. Interestingly, we have also identified an inverted MED-1 complex, that we had termed iMED, upstream of the initiation site of the human MDR1 promoter (Thayer, 1999) . Mutation of iMED decreased transcription in drugsensitive cells, suggesting a function of this element in constitutive MDR1 transcription. Although its role in drug-resistant cells has not been directly investigated, a recent study suggests that binding of one of the MED-1 (iMED) complex partners may be increased in drugresistant leukemia cells (Labialle et al., 2002) , possibly linking iMED to the activation of MDR1 in certain drug-selected cells. Interestingly, several other drug transporters, including MRP1 and MRP2, also utilize multiple start sites; whether a MED-1-like element is involved in their regulation is under investigation.
MEF-1
A 130-kDa protein, termed MDR1 promoter-enhancing factor 1 (MEF1), has been shown to activate MDR1 transcription through an upstream promoter element (À118 to À111). Significantly, this protein was present in a drug-resistant HL60 subline, but not in the drugsensitive HL60 parent cells (Ogretmen and Safa, 2000) , thereby suggesting a direct role in MDR1 activation following drug selection. An interesting correlate has been found in MCF-7 cells, where it appears that the same promoter element binds an inhibitory complex containing NF-kB and c-Fos in parental cells, but not in resistant MCF-7/ADR cells (Ogretmen and Safa, 1999) . The mechanism by which MEF1 or iMED regulates MDR1 transcription, the interplay between MEF1 and NF-kB/c-Fos and the frequency with which these complexes are involved in MDR1 activation in drugresistant cells remain to be determined.
Gene rearrangements
In addition to altering the expression or activity of transacting factors, the transcriptional output of genes can also be affected by more dramatic and permanent genomic alterations, such as translocations and mutations. An MDR1-overexpressing cell line selected for resistance to adriamycin was found to harbor a (4q;7q) translocation, resulting in a hybrid mRNA containing sequences from both MDR1 and a novel gene normally located on chromosome 4 (Mickley et al., 1997) . This gene rearrangement allowed for the activation of MDR1 expression by promoter sequences found within the translocated chromosome 4 DNA. Additional gene rearrangements have been identified in other MDR cell lines (Knutsen et al., 1998) and in some patient tumors (vide infra), suggesting that this may be a significant mechanism for the overexpression of otherwise silent Pgp genes in acquired drug resistance. In addition, MDR1 promoter mutations that may alter transcription have also been identified (Stein et al., 1994) and may have relevance in the clinical setting (vide infra) (Fromm, 2002) .
Constitutive repression in drug-sensitive cells
Thus far, we have discussed transcription as the interaction between transcription factors and their cognate DNA binding sites. However, superimposed upon the regulation mediated by those interactions is the role of chromatin in permitting this interplay to occur. The basal transcriptional state of chromatin is inactive -the DNA wrapped in a nucleosomal complex is generally inaccessible to transcription factors. However, chromatin is a dynamic structure that receives signals from the environment to trigger changes in chromosomal architecture. The past decade has witnessed an evolution in the field of chromatin-regulated transcription. A number of elegant studies have shown that covalent modifications of the amino-termini of the core histones in nucleosomes are critical to the regulation of transcription. These modifications, which include acetylation, methylation, phosphorylation and ubiquitination, appear to occur in sequential patterns, leading to the hypothesis that their intercommunication provides a 'histone code' that, when deciphered by other components of the transcriptional machinery, signals for transcriptional activation/deactivation (Berger, 2002) . Two classes of chromatin-targeted proteins have been identified that act as on/off switches for transcriptional competence: chromatin remodeling proteins and chromatin-modifying enzymes. Chromatin-modifying enzymes, specifically histone acetylases (HATs)/histone deacetylases (HDACs) and DNA methylases, have been shown to be involved in the regulation of the MDR1 gene.
Acetylation: the HATS and the HDACs (reviewed in Narlikar et al., 2002) In 1996, the first HAT was isolated from Tetrahymena (Brownell et al., 1996) , sparking a renewed interest in the role that chromatin modifications play in gene regulation. The silencing of gene expression is associated with deacetylated histones, while histone acetylation neutralizes the positive charge of the lysine-rich histone tails, thereby weakening the interaction of histones with the negatively charged DNA and generating an 'open' chromatin conformation. Moreover, acetylation of the transcription factors themselves can add an additional layer of regulation to this process. Histone acetylation is reversed by the action of the histone deacetylase (HDAC) family of chromatin-modifying enzymes (Figure 3 ). How these modifying enzymes are recruited to specific promoters at specific times is still under intensive investigation. However, a general model proposes that HDACs are recruited to the promoter by sequence-or modification-specific (vide infra) proteins, thereby maintaining the gene in a hypoacetylated, inactive state. In response to specific stimuli, transcriptional activators recruit the HATs that acetylate histones, resulting in conformational changes within the nucleosomal array. Treatment of cells with the HDAC inhibitors trichostatin A or sodium butyrate leads to the activation of MDR1 transcription and associated hyperacetylation of MDR1 proximal-promoter histones (Jin and . We have shown that this activation is mediated by the HAT protein, P/CAF, which is recruited to the promoter via its interaction with a transcriptional complex that we termed the MDR1 enhancesome (vide infra). Interestingly, activation appears to be limited to cells that already express detectable levels of MDR1 RNA. In the few cell types in which the MDR1 gene is silenced, altering the equilibrium of chromatin acetylation is not sufficient to activate transcription. Recent studies suggest that this may be the result of hypermethylation of the MDR1 promoter, which acts as the ultimate 'lock-down' of gene expression (vide infra).
Activation of the MRP7 promoter by TSA has also been observed, although the mechanistic basis of this activation has not been elucidated (Kao et al., 2003) . Interestingly, in HepG2 cells, TSA repressed transcription of the MRP2 gene through an upstream region (À517 to À197), suggesting that chromatin modification may permit binding of a repressor complex to this promoter (Stockel et al., 2000) ; TSA had no effect on the expression of MRP3 in these studies.
DNA methylation
The role of DNA methylation in transcriptional silencing is best known with respect to X-chromosome inactivation. However, an increasing body of evidence indicates that DNA methylation significantly contributes to the activation and repression of many different genes (reviewed in Jones, 2003; Kalebik, 2003) , including MDR1 (Figure 4) . Over the past several years, there have been numerous studies on MDR1 promoterassociated methylation, but interpretation of these observations has been hampered by a relative dearth of knowledge regarding the mechanistic basis of methylation-associated transcriptional repression. However, a recent link between DNA methylation and histone acetylation has been established, since it has been shown that a methyl-DNA-binding protein, MeCP2, interacts with HDACs (el-Osta et al., 2002). The prevailing hypothesis is that methylation status helps to define the acetylation state of local chromatin, whereby hypomethylated DNA is transcriptionally active and hypermethylated, deacetylated chromatin provides a barricade to the transcriptional machinery.
Using chromatin immunoprecipitation methods it has been shown that, in certain leukemia cell lines in which MDR1 expression is undetectable, the MDR1 promoter is methylated and assembled into chromatin enriched with MeCP2 and deacetylated histone (El-Osta and Wolffe, 2001; El-osta et al., 2002) . Treatment of cells with a demethylation agent activates the MDR1 gene with subsequent release of MeCP2. Although initially resistant to HDAC inhibitors, following demethylation the MDR1 promoter can be further activated by these agents, consistent with the notion that DNA methylation supersedes chromatin acetylation with regard to repression of the MDR1 promoter. The role of chromatin in the regulation of other drug transporters has not yet been investigated.
Stress induction of drug-resistant genes
Given the role of MDR1 in protection against environmental adversity, it is not surprising that the MDR1 gene is highly responsive to stress signals (reviewed in Scotto and Egan, 1998) . MDR1 inducers include heat shock, partial hepatectomy, inflammation, exposure to carcinogens including chemotherapeutics, hypoxia and UV and X irradiation. The effect of these inducers on the transcription of other drug transporters has just begun to be investigated.
Heat shock
Activation of MDR1 gene expression by heat shock and heavy metals was first reported by Gottesman and coworkers (Chin et al., 1990b) and proposed to be mediated by a single mechanism. A heat-shock element (HSE) identified at position -152 to -178 was shown to interact with heat-shock factor (HSF); a second HSElike element (-99 to -66) bound to a protein complex which was largely unchanged upon heat shock (Miyazaki et al., 1992) . However, the functional role of these elements in heat-shock response was not evaluated. More recently, it has been shown that activation by heat shock requires the interaction of HSF1 with the -152/ -178 HSE, while activation by other stress agents, including arsenite, butyrate and etoposide occur independent of this HSE and HSF1 (Vilaboa et al., 2000) . Indeed, activation by these and other stress inducers has been shown to occur through another promoter region, which we have termed the 'MDR1 enhancer' (vide infra).
Inflammation (GR and C/EBPb)
The 'acute-phase response' is a general term for the complex changes that take place in mammals in response to inflammatory stimuli such as bacterial infection or burn injury. This response is often experimentally simulated in rodents by the administration of bacterial lipopolysaccharide (LPS). In response to LPS, macrophages secrete inflammatory cytokines such as interleukin (IL)-1, IL-6 and TNF, which in turn act on the liver to induce a change in that organ's gene expression program, resulting in the synthesis of a range of acute-phase proteins (reviewed in Akira and Kishimoto, 1992) . Most of the analyses of the expression of drug transporters during inflammation have relied on the rodent model system; thus, data have been obtained primarily for the transcription of the rodent homologues. Although not necessarily directly applicable to the human genes, the high degree of promoter conservation among family members, together with the similar response of the human and rodent genes to inflammatory agents, suggests that similar transcription pathways exist.
Under acute-phase conditions, Pgp genes are induced in the liver (Nakatsukasa et al., 1993) . Interestingly, at least two transcription factors that are known to be induced during the acute-phase response have been shown to regulate Pgp gene expression in some cell lines. Studies carried out in a number of laboratories have shown that the IL-6-induced CAAT enhancer-binding protein (C/EBPb) can activate the mouse and human MDRI genes in transfection assays (À147 to À139 in the human gene) (Combates et al., 1994; Yu et al., 1995) . Our laboratory has shown that the homologous region in the hamster pgp1 promoter also contains a C/EBPbbinding site (Egan, 1997) and that activation through this site can be modulated by the binding of the glucocorticoid receptor (GR) (vide infra). These results suggest that this element may be important as a site of crosstalk between the inflammatory signals, mediated by cytokines through C/EBPb, and the anti-inflammatory signals, mediated by glucocorticoids through their receptor. The C/EBPb inducer IL-6 was also shown to induce MRP2 expression and activity in human hepatoma cell lines (Lee and Piquette-Miller, 2001 ); the presence of a C/EBPb-binding site within the upstream region of the MRP2 promoter (À356 to À343) suggests that this increase is mediated at the level of transcription (Tanaka et al., 1999) .
A number of studies have suggested a role for glucocorticoids in the transcription of MDR1 homologues, but the responses appear to be cell type specific. Using the mouse hepatoma cell lines Hepa 1-6 and hepa1c1c, it was found that the synthetic glucocorticoid, dexamethasone, elicited an increase in the expression of the two murine MDR1 homologues, mdr1a and mdr1b (Zhao et al., 1993) . Nuclear run-on analysis indicated that this increase occurred at least in part at the transcriptional level and could be abrogated by the protein synthesis inhibitor cycloheximide, suggesting that GR was influencing this promoter through an indirect mechanism. A similar increase in human MDR1 RNA levels was observed in the HepG2 human hepatoma cell line. In rat primary hepatocytes, however, dexamethasone treatment led to a decrease in mdr1b expression, and no increase was seen in the nonhepatoma mouse LMtk-and NIH3T3 cell lines or in the human HeLa cell line upon dexamethasone treatment, suggesting that the effect is cell line specific.
A glucocorticoid response element (GRE) has been identified by our laboratory in the promoter of the hamster MDR1 homologue, pgp1 (Egan and Scotto, 1996) . This site, between À96 and À83, mediates the repression of pgp1 transcription by GR in both DC-3F Chinese hamster lung cells and a human osteosarcoma cell line, U2-OS. The GRE overlaps a binding site for CEBPb (vide supra) and it appears that GR represses pgp1 transcription by interfering with the actions of CEBPb, as both sites are required for repression to occur. Interestingly, these elements are conserved in the human MDR1 gene and MDR1 transcription can also be repressed by GR in some cell types, suggesting that a similar mechanism may be involved. Treatment of rats with dexamethasone increases MRP2 mRNA in vivo, although the mechanism underlying this increase has not yet been determined (Courtois et al., 1999) . The fact that glucocorticoids are currently used in chemotherapy for many tumors, including chronic lymphocytic leukemias, lymphomas, multiple myelomas and breast cancers makes an understanding of the role of these hormones in the regulation of drug transporters an important goal.
Hypoxia
The microenvironment of many large, rapidly growing tumors lacks a sufficient vascular supply, resulting in oxygen deprivation or hypoxia. Prolonged hypoxia has been linked to metastasis, since it increases genomic instability, genomic heterogeneity, and may act as a selective pressure for tumor cell variants (Subarsky and Hill, 2003) . This hypoxic environment results in the induction of many stress-response genes, including glycolytic enzymes, proangiogenic factors and proinflammatory genes (Semenza, 1998) . Apropos of this, it has recently been shown that Pgp expression is increased in hypoxic cells, and that this increase is mediated by hypoxia-inducible factor-1 (HIF-1), a transcription factor that normally resides in the cytoplasm of normoxic cells and is believed to be shuttled to the nucleus upon hypoxic stress. HIF-1 activates the MDR1 promoter through a consensus binding sequence (5 0 GCGTG3 0 ; À49 to À45) that overlaps the GC element involved in constitutive vide supra and inducible vide infra expression. Indeed, preliminary evidence suggests that the GC-binding protein Sp1 may be involved in the hypoxic response. These results may in part explain the observation that hypoxic tumor cells are more refractory to anticancer agents (Brown and Giaccia, 1998) .
Carcinogens
Most early studies on the effects of carcinogens on Pgp expression concentrated on the rat genes. These genes are induced by a number of xenobiotics including 2,3,7,8-tetrachlorodibenzo-p-dioxin (Teeter et al., 1991a, b) , 2-acetylaminofluorene (2-AAF) (Gant et al., 1991; Schrenk et al., 1994; Hill et al., 1996; Lecureur et al., 1996) and 3-methylcholanthrene . The transcriptional mechanism underlying this activation was elusive until it was shown that activation of rat mdr1b by 2-AAF involves an NF-kB-binding site at position À167 to À158 within the promoter. 2-AAF was found to activate mdr1b through the generation of reactive oxygen species, leading to the activation of IkB kinase, the degradation of IkB beta and the activation of NF-kB (Deng et al., 2001) . A different mechanism has recently been shown to mediate hepatic induction of the human MDR1 gene by 2-AAF. In this case, the carcinogen activates phosphoinositide 3-kinase and its downstream effectors Rac1, NAD(P)H oxidase and Akt, resulting in activation of MDR1 through an upstream binding site (À6092) that includes an NF-kB-binding site (Kuo et al., 2002) .
Chemotherapeutics
Considerable evidence has accumulated to indicate that the expression of drug transporter genes can be transiently induced in response to chemotherapeutics (Kohno et al., 1989; Gekeler et al., 1998; Chin et al., 1990a; Asakuno et al., 1994; Hu et al., 1995; Ohga et al., 1996; Ichihashi and Kitajima, 2001; Brugger et al., 2002; Liu et al., 2002) . This was first reported in CCRF-CEM/ ActD cells that exhibited an increased steady-state level of MDR1 RNA following short-term exposure to actinomycin D (Gekeler et al., 1998) ; this increase was mediated, at least in part, at the level of transcription. Early studies indicated that the MDR1 promoter region from À136 to À76 was involved in activation by actinomycin D (Ohga et al., 1996) ; this region was further delineated to the MDR1 enhancesome (Hu and Scotto, unpublished, 2000) . Although it was initially assumed that only those drugs associated with the MDR phenotype would induce the expression of Pgp genes, more recent studies indicate that MDR1 transcription can also be induced by non-MDR drugs, such as antifolates and hydoxyurea (Chaudhary and Roninson, 1993) . In this study, induction of MDR 1 was associated with morphological indications of cell damage, suggesting that increased Pgp transcription may be part of a general cellular response to damaging agents. Interestingly, some drugs, such as mitomycin C, suppress the activity of MDR1, although the mechanism by which this occurs has not been determined (Ihnat et al., 1997) . It should also be noted that overexpression of MDR1 in response to chemotherapeutics was shown to be a result of changes in mRNA stabilization and translational initiation in several leukemia cell lines, with no apparent transcriptional component (Yague et al., 2003) . Thus, it is likely that multiple mechanisms exist in different cell types that either cooperatively or exclusively regulate MDR1 gene output. While few studies have focused on the regulation of other drug transporters by chemotherapeutic agents, MRP2, MRP3 and MRP5 were shown to be induced in liver HepG2 cells by cisplatin, although the mechanism underlying this induction was not investigated .
It has been well established that MDR1 gene expression can be activated by UV radiation, differentiation agents such as sodium butyrate and retinoic acid, HDAC inhibitors, phorbol esters and certain chemotherapeutics. Recent studies in our laboratory indicate that the signals from all these divergent stimuli converge on a region of the MDR1 promoter that we refer to as the 'MDR1 enhancesome' (Figure 5 ) (Jin and Scotto, 1998; Hu et al., 2000; Markenson et al., unpublished) . This region includes binding sites for the trimeric transcription factor NF-Y and the Sp family of GC-binding transcription factors. Together, these DNA-binding proteins cooperate to recruit the histone acetyltransferase P/CAF to the MDR1 promoter, resulting in the acetylation of promoter-proximal histones and subsequent transcriptional activation that is likely mediated by further chromatin remodeling. Recently, chromatin immunoprecipitation studies have identified a 'switch' in DNA-binding Sp family members following induction (Ying and Scotto, unpublished) . Studies are presently underway to determine whether this change in binding factors results in recruitment of new coactivators/ corepressors to the MDR1 promoter, and whether other factors that have been shown to bind to the MDR1 GC element are also involved in stress response through the enhancesome complex. Although the mechanism by which each agent transduces the signal that results in promoter activation has yet to be determined, the role of the MDR1 enhancesome in the regulation of transcription by a variety of stimuli makes it an attractive target for therapeutic intervention.
Nuclear receptors and transcription of drug transporters
While many ABC transporters are ubiquitously expressed, high levels of expression are usually restricted to a limited number of tissues or cell types where they perform a specialized function. One organ that depends on the action of ABC transporters to carry out its prescribed function is the liver. In addition to MDR1, which is involved in lipid transport and drug biodistribution and is activated during inflammation and partial hepatectomy of the liver (vide supra), several other drug transporters are involved in liver function, including MRP2, MRP3 and BSEP (ABCB11). The major physiological role of MRP2 is to transport conjugated metabolites into the bile canaliculus, while MRP3 is localized in the basolateral membrane of the hepatocytes and transports similar metabolites back to the bloodstream. This may explain why mutation of MRP2 leads to Dubin-Johnson syndrome, characterized by elevated levels of bilirubin, increased urinary coporphyrin I fraction and deposition of dark pigment in the liver. Monoanionic bile salts are secreted into bile canaliculi by the bile salt export pump BSEP (see Meier and Stieger, 2002 for review) . Given the functional relationship among these transporters, it is not surprising that their transcription is regulated through similar mechanisms involving nuclear hormone receptors.
Nuclear receptors are comprised of a family of transcription factors that function as heterodimers to regulate target promoters. RXR (retinoid receptor) is present in all heterodimers; the second partner determines the substrate ligand and the target promoters that will be activated (see Freedman, 1999 for review). The nuclear receptor proteins that have been shown to be involved in transcription of drug transporters include retinoic acid receptor (RAR), farnesoid receptor (FXR) steroid-activated receptor (SXR; P(pregnane)XR in rodents) and constitutive androstane receptor (CAR). The RXR-containing heterodimers regulate a broad range of hepatic metabolic functions, including bile acid synthesis, fatty acid and oxysterol metabolism, and cytochrome oxidase drug metabolism.
RARa in complex with RXRa has been shown to regulate transcription of the rat MRP2 promoter through a binding element located in the upstream promoter region (À422 to À398) (Denson et al., 2000) ; the cytokine IL-1b suppresses activation through this site. Although the MDR1 promoter is activated in neuroblastoma cell lines by all-trans retinoic acid (ATRA), activation appears to be independent of RAR/RXR binding and is instead mediated by the differential binding of Sp family members to the GC element within the MDR1 enhancesome (Thayer, 1999) .
FXR, when combined with RXR and bile salts as its ligand, initiates feedback control of bile acid synthesis (Redinger, 2003) . Both BSEP and MRP2 are targets of the FXR : RXR heterodimer. An FXR response element identified in the human BSEP promoter (À192 to À180) mediates the activation of BSEP transcription by bile salts; a similar element exists in the rat BSEP promoter (À64 to À52). Moreover, FXRÀ/À mice exhibit a dramatic decrease in the expression of BSEP, consistent with the role of this receptor in regulation of BSEP transcription. Notably, lithocolic acid, a potent inducer of choleostasis, decreases the transcription of BSEP by antagonizing the activity of FXR, implicating FXR and loss of BSEP in intrahepatic choleostasis (Yu et al., 2002) .
An atypical promoter element has been identified within the rat MRP2 promoter (À401 to À376) that interacts with FXR and mediates transcriptional activation. This binding site also mediates the transcriptional regulation of MRP2 by PXR (SXR) (a receptor for xenobiotics such as rifampin, phenobarbital, taxol, clotrimazole and hyperforin) and by CAR (Kast et al., 2002) . Interestingly, the human MDR1 promoter has also been shown to be regulated by the interaction of SXR : RXR with a promoter element B8 kb upstream of the transcription start site (Geick et al., 2001; Synold et al., 2001) . Taken together, these results suggest that activation of drug transporters through multiple nuclear receptors can alter the efflux, and therefore the pharmacokinetics and bioavailability of a variety of compounds, including chemotherapeutic agents. Notably, despite the presence of putative nuclear receptor binding sites within the MRP3 promoter, regulation of MRP3 by bile salts in enterocytes is mediated by the interaction of the alpha fetoprotein transcription factor (FTF) with the MRP3 promoter (À229 to À138) (Inokuchi et al., 2001) ; how this promoter is regulated in liver cells is presently under investigation.
See Figure 6 for a schematic of the transcription factors known to regulate the MDR1 promoter. Note that several of the binding sites for transcription factors overlap, and in most cases it is not yet known whether multiple factors can co-occupy their cognate promoter site at the same time, or whether their interaction with the promoter is mutually exclusive. An overview of the factors presently known to regulate the transcription of other ABC drug transporters is shown in Table 3 . Keep in mind that most of the studies identifying these factors were performed in tissue culture cells and the relevance Figure 5 A variety of environmental signals, including those induced by hormones (ATRA), radiation, HDAC inhibitors (TSA, butyrate), some chemotherapeutics, phorbol esters and others converge on the MDR1 enhancesome, which includes the DNAbinding proteins Sp1, Sp3 and NF-Y, the histone acetylases P/CAF and P/300. Depending on conditions, the transcription factors egr1, WT-1 and the corepressor HDAC1 may also be found at the promoter of these findings to the in vivo situation, particularly in the clinical setting, remains to be determined.
Transcriptional regulation of drug transporters -clinical relevance
The analysis of the transcriptional regulation of the ABC drug transporters is an ongoing process, and additional layers of complexity are likely to be uncovered in a relatively short period of time. If MDR1 is the prototype, one can envision a level of intricacy that will rival a spider's web. However, it must be kept in mind that most of the studies to date have been performed in cultured cells, and how these observations will translate to the in vivo situation and, importantly, to the clinic, remains to be seen. Nevertheless, some of the laboratory studies have been validated in the clinical setting, generating confidence that many of these in vitro findings will eventually be relevant to the human situation.
Gene rearrangements and mutations
Studies in drug-resistant cell lines suggested that random chromosomal rearrangements could 'trap' MDR1 in close proximity to a constitutively active heterologous promoter, resulting in aberrant activation of the MDR1 gene (vide supra). This has also been observed in a subset of drug refractory acute lymphocytic leukemias, where a breakpoint was identified between MDR1 and sequences 500-1000 kb distant to the gene, suggesting that the MDR1 gene may be a 'hot spot' for rearrangements in human tumors.
In a study evaluating MDR1 promoter mutations in human tumors, 15 of 39 patients were found to have a point mutation (T-C transition) at þ 8 relative to the start site of transcription (Rund et al., 1999) . In a second study evaluating the role of MDR1 mutations and polymorphisms in colo-rectal cancer, naturally occurring mutations in the promoter region were associated with colon cancers exhibiting high microsatellite instability (Potocnik et al., 2002) . Although the effect of these mutations on transcriptional output has not yet been investigated, it is intriguing to speculate that both polymorphisms and mutations within the MDR1 promoter in human tumors may affect therapeutic efficacy.
Rapid activation by chemotherapeutics
Several studies have shown that the MDR1 gene can be transiently induced in cultured cells following exposure to chemotherapeutic agents. We have shown that a similar rapid induction occurs in patient tumors during the course of chemotherapy (Abolhoda et al., 1999) . Metastatic sarcoma tumors isolated from patients while they were undergoing chemotherapy (doxorubicin) exhibited a rapid (within 10 min) induction (up to 10-fold) of MDR1 expression, with no induction observed in adjacent (lung) tissue. The rapidity of this response excludes gene rearrangement or mutations and supports transcriptional activation as the underlying mechanism. These results suggest a greater and heretofore unconsidered role of MDR1 in the induction of, rather than the selection for, solid tumor drug resistance (Figure 7) . Moreover, the recent observations linking MDR1 to a general antiapoptotic mechanism, taken together with the transcriptional induction of MDR1 by a variety of stress inducers, indicate that this gene may play a role in determining the efficacy of therapeutic regimens not previously considered (i.e. non-MDR drugs, radiation). More recently, MRP1 expression was shown to increase following chemotherapy of primary melanoma (Ichihashi and Kitajima, 2001) , underscoring the need for novel approaches aimed at regulating drug transporter expression.
Epigenetic events
It is easy to envision that alterations in either the methylation or acetylation status of the chromatinembedded MDR1 promoter can have dramatic effects on its expression, and aberrant changes in chromatin structure that oft-times accompany tumorigenesis can lead to dysregulation of drug-resistant genes. Several studies have investigated the methylation status of the MDR1 gene in human tumors. In one study, MDR1 Figure 6 Schematic of the MDR1 promoter with factors known to regulate its transcription (see text). Note that some binding sites overlap, and it is likely that different factors interact with these sites under different conditions. With the exception of PCAF, which is recruited to the MDR1 promoter through interaction with NF-Y and Sp proteins, all other factors shown interact directly with DNA. Note that TCF/LEF binds to several sites within the MDR1 promoter, ranging from -1813 to -261; only one site is shown was found to be hypermethylated in 28% of colorectal cancers (Shannon and Iacopetta, 2001 ). In a separate study, methylation of MDR1 was evaluated in acute leukemias at initial presentation (Issa et al., 2002a) and following relapse (Issa et al., 2002b) . MDR1 was methylated in 24.5% of patients at initial presentation, with 28% of the patients showing an increase in methylation of MDR1 at relapse compared to the initial pattern; notably, the expression of MDR1 inversely correlated with the degree of methylation. Thus, methylation appears to be a viable mechanism by which tumor cells can inactivate the MDR1 gene, possibly as a step in the pathway to tumorigenesis. Molecular pathways regulating epigenetic events that occur during tumorigenesis are being exploited as new targets for therapeutic intervention. Indeed, clinical studies exploring the effectiveness of agents targeting DNA methylation and histone acetylation are underway (Kalebik, 2003) . As a cautionary note, resistance genes silenced by methylation/deacetylation in certain tumors are likely to be reactivated by these agents, potentially confounding efficacy by generating a subset of drugresistant tumor cells.
Conclusions and future prospects
The complex transcriptional regulation of MDR1, the grand-daddy of ABC drug transporters, has been well deciphered over the past decades. However, rapid advances in the transcription field indicate that our understanding of MDR1 transcription may still be in its infancy, and dissection of the regulation of other drug transporters lags far behind. Nevertheless, studies suggest that transcription of MDR1, as well as other drug transporters, may provide a future therapeutic target in our quest to prevent and ultimately eradicate resistance to cancer therapeutics. To date, efforts to combat the overexpression of Pgp in the clinic have involved the use of functional modulators, or 'reversal agents,' that block the Pgp-mediated efflux of anticancer agents. One could envision a scenario in which prophylactic intervention could prevent the transcriptional activation of drug transporters, rather than block their function subsequent to overexpression. Indeed, studies aimed at targeting MDR1 transcription are underway (see Scotto and Johnson, 2001 for review), utilizing drugs such as the transcriptional inhibitor ET-743 (Friedman et al., 2002) , and novel MDR1-specific inhibitory zinc-finger peptides that block interactions with the GC element (Bartsevich and Juliano, 2000) . One hopes that, as our knowledge of the transcriptional mechanisms regulating drug transporters expands, so will our armamentarium of agents with which to combat drug resistance. 
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